@article{1b0a66a1136949eab7064f4c6538967e,
title = "Prevalence of Bronchiectasis in Patients with Chronic Rhinosinusitis in a Tertiary Care Center",
abstract = "Background: Whereas chronic rhinosinusitis (CRS) is associated with asthma, and vice versa, the association between CRS and other lower respiratory conditions is not well-established. Bronchiectasis is characterized by permanent damage of the airways, and as many as 45% of bronchiectasis patients have CRS, but the prevalence of bronchiectasis among CRS patients is not known. Objective: To determine the prevalence of bronchiectasis among CRS patients and to characterize demographic and clinical features of patients with bronchiectasis and CRS. Methods: Electronic medical records of patients with rhinosinusitis were searched by computer algorithm supplemented with manual chart review to identify patients with CRS, asthma, and/or bronchiectasis. Demographic and clinical features and antibiotic courses for sinopulmonary infections 2 years before and after sinus surgery were obtained by manual chart review. Results: The prevalence of bronchiectasis as determined by International Classification of Diseases, Ninth Revision code was significantly higher in CRS patients than in asthmatic patients (2.3% vs 1.7%; P < .003). Similarly, based on a text word search of “bronchiectasis” in the chest computed tomography (CT) scan reports, patients with CRS who had chest CT scans had a higher prevalence of bronchiectasis than did asthmatic patients with chest CT scans (24.3% vs 19.5%; P = .005). Patients with CRS and concurrent bronchiectasis did not have a reduction in the frequency of sinopulmonary infections after sinus surgery compared with patients with CRS without bronchiectasis (P < .05). Conclusions: Bronchiectasis is an important comorbidity in patients with CRS and may identify a severe phenotype of chronic sinonasal disease.",
keywords = "Antibiotics, Asthma, Bronchiectasis, CRSsNP, CRSwNP, Chronic rhinosinusitis, Nasal polyp, Prevalence",
author = "Peters, {Anju T.} and Sumit Bose and Amina Guo and Newton Li and Mariel Benjamin and Michelle Prickett and Villareal, {Raul S.} and Amy Yang and Atsushi Kato and Kern, {Robert C.} and Tan, {Bruce K.} and Grammer, {Leslie C.} and Schleimer, {Robert P.} and Conley, {David B.} and Smith, {Stephanie S.} and Welch, {Kevin C.} and Stevens, {Whitney W.}",
note = "Funding Information: This work was supported by the Chronic Rhinosinusitis Integrated Studies Program (U19 AI106683 and P01 145818); National Institutes of Health grants (KL2 TR001424, K23 AI141694, R01 AI37174), the Parker B. Francis Fellowship Foundation, the HOPE APFED/AAAAI Pilot Grant Award, and the Ernest Bazley Foundation.Conflicts of interest: A.T. Peters has served as an advisor to Sanofi, AstraZeneca, GSK, and Optinose. R. P. Schleimer reports grants from the National Institutes of Health during the conduct of the study; and reports personal fees, equity, or both from serving as a consultant for Intersect ENT, GlaxoSmithKline, Allakos, Aurasense, Merck, BioMarck, Sanofi, AstraZeneca/Medimmune, Genentech, Exicure, Inc, Otsuka, Inc, Aqualung Therapeutics Corp, and ActoBio Therapeutics, outside the submitted work. In addition, R. P. Schleimer has Siglec-8 and Siglec-8 ligand-related patents licensed to Allakos, Inc. W. W. Stevens has served as an advisor to GlaxoSmithKline, Bristol Myers Squibb, and Genentech. The rest of the authors declare they have no relevant conflict of interests. Funding Information: This work was supported by the Chronic Rhinosinusitis Integrated Studies Program ( U19 AI106683 and P01 145818 ); National Institutes of Health grants ( KL2 TR001424 , K23 AI141694 , R01 AI37174 ), the Parker B. Francis Fellowship Foundation , the HOPE APFED / AAAAI Pilot Grant Award, and the Ernest Bazley Foundation . Publisher Copyright: {\textcopyright} 2021 American Academy of Allergy, Asthma & Immunology",
year = "2021",
month = aug,
doi = "10.1016/j.jaip.2021.04.054",
language = "English (US)",
volume = "9",
pages = "3188--3195.e2",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",
number = "8",
}